Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022
Compugen Ltd. - Ordinary Shares (CGEN)
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
cgen.com/investors/overview
Company Research
Source: PR Newswire
Clinical data from dual combination COM701/nivolumab MSS-CRC cohort expansion studyResearch data on differentiation of PVRIG from other immune checkpointsHOLON, Israel, Oct. 6, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that it will present new clinical data from its dual combination COM701/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 10-12 November 2022, Boston, MA. Oral presentation details:Title: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastasesAbstract Number: 659Session Title: Clinical Development of Novel Checkpoint InhibitorsSession Date Thursd
Show less
Read more
Impact Snapshot
Event Time:
CGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEN alerts
High impacting Compugen Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CGEN
News
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024PR Newswire
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503PR Newswire
- Compugen to Participate in Two Upcoming Investor ConferencesPR Newswire
- Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount? [Yahoo! Finance]Yahoo! Finance
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer ImmunotherapyPR Newswire